Condition
Choroidal Neovascularization
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 8 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
8 shownEffect of Video Viewing on Intravitreal Injection ExperienceNCT07002372 · 2025-05-05
RECRUITINGAn Interpretable Fundus Diseases Report Generating System Based On Weakly LabelingsNCT06918028 · 2025-05-01
NOT_YET_RECRUITINGOCTA Metrics Repeatability and Reproducibility in Different DisordersNCT04488887 · 2020-08-01
UNKNOWNEffect of Corona Virus on Intravitreal InjectionsNCT05494775 · 2019-02-01
UNKNOWNZiv-aflibercept in Ocular Disease Requiring Anti-VEGF InjectionNCT02486484 · 2015-03-01
UNKNOWNAn Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.NCT01908816 · 2013-09-26
COMPLETEDPF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)NCT01445899 · 2012-02-01
COMPLETEDIntravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot StudyNCT00855608 · 2009-03-01
UNKNOWNCommon interventions
ranibizumabDRUG2adalimumabDRUG1Anti-vascular endothelial growth factors (Anti-VEGFs)DRUG1Optical coherence tomography angiographyDIAGNOSTIC_TEST1PF-04523655 (Stratum I)DRUG1PF-04523655 (Stratum II)DRUG1Procedure video viewingBEHAVIORAL1With fundus diseasesOTHER1Without fundus diseasesOTHER1ziv-afliberceptDRUG1
Leading sponsors
Trial status mix
UNKNOWN4
COMPLETED2
NOT_YET_RECRUITING1
RECRUITING1
Phase mix
NA2
PHASE22
PHASE11
PHASE31
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.